GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Gross Profit

GlobeStar Therapeutics (GlobeStar Therapeutics) Gross Profit : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Gross Profit?

GlobeStar Therapeutics's gross profit for the three months ended in Dec. 2023 was $0.00 Mil. GlobeStar Therapeutics's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. GlobeStar Therapeutics's gross profit for the three months ended in Dec. 2023 was $0.00 Mil. GlobeStar Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, GlobeStar Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

GlobeStar Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of GlobeStar Therapeutics was 48.45%. The lowest was 9.52%. And the median was 28.99%.


GlobeStar Therapeutics Gross Profit Historical Data

The historical data trend for GlobeStar Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Gross Profit Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.04 - - -

GlobeStar Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlobeStar Therapeutics's Gross Profit

For the Biotechnology subindustry, GlobeStar Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeStar Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's Gross Profit falls into.



GlobeStar Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

GlobeStar Therapeutics's Gross Profit for the fiscal year that ended in Sep. 2023 is calculated as

Gross Profit (A: Sep. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

GlobeStar Therapeutics's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

GlobeStar Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


GlobeStar Therapeutics  (OTCPK:GSTC) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

GlobeStar Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


GlobeStar Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550